$19.36
0.653.47%
Last update: Nov 10, 7:12 AM
Immunome Inc
IMNMNASDAQ
Immunome rose 17.8% from $16.44 to $19.36, ahead of the S&P 500's +10.5%. Its worst day was Dec 17 (−15.8%), and its low came Nov 10 at $16.44.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Immunome shares fell 15.8%, while the S&P 500 fell 1.1%.
−15.8%, the year's worst day · S&P 500 −1.1%
Immunome shares rose 10.1%, while the S&P 500 rose 0.3%.
Story events cover the past 12 months · Times ET
+10.1% · S&P 500 +0.3%
EPS of $-0.75 missed the $-0.60 estimate on $0.00 revenue (est. $784,620.00).
+4.5% · S&P 500 +0.7%
Immunome shares rose 13.3%, while the S&P 500 rose 2.9%.
+13.3% · S&P 500 +2.9%
EPS of $-0.48 beat the $-0.56 estimate on $0.00 revenue (est. $533,336.00).
−2.2% · S&P 500 +0.6%
Immunome shares rose 9.9%, while the S&P 500 fell 0.1%.
+9.9% · S&P 500 −0.1%
EPS of $-0.65 missed the $-0.51 estimate on $0.00 revenue (est. $533,336.00).
+6.6% · S&P 500 +0.3%
Where it ended: a close of $19.36 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 2, 2027 (EPS est. $-0.64, revenue est. $506,664.00).
Nothing in the past 12 months.
All IMNM dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IMNM and SPY from Benzinga historical bars. Not investment advice.
